Showing 5471-5480 of 5956 results for "".
- OD-OS to Showcase Navilas Navigated Retinal Laser Therapy at EURETINAhttps://modernod.com/news/od-os-to-showcase-navilas-navigated-retinal-laser-therapy-at-euretina/2476852/OD-OS will share clinical experiences with the Navilas 577s digital treatment platform this week at the EURETINA Congress in Paris. Navigated retinal laser therapy with the Navilas 577s allows for panretinal photocoagulation with uniform spot distribution, which is faster and less painful for pat
- Oxurion Completes Enrollment of Phase 1 Clinical Trial Evaluating THR-687 for the Treatment of DMEhttps://modernod.com/news/oxurion-completes-enrolment-of-phase-1-clinical-trial-evaluating-thr-687-for-the-treatment-of-dme/2476849/Oxurion NV announced the completion of enrollment of patients in a phase 1 trial with THR-687. The open-label, multicenter, dose escalation phase 1 study is evaluating the safety of a single intravitreal injection of escalating dose levels (3) of THR-687 for the treatment of patients with diabeti
- Alcon Names Carla Mack, OD, Global Head of Professional Affairs for Vision Carehttps://modernod.com/news/alcon-names-carla-mack-od-global-head-of-professional-affairs-for-vision-care/2476847/Alcon has announced that Carla Mack, OD, has been named Global Head, Professional Affairs. In her new role, Dr. Mack leads professional affairs within Alcon’s Global Vision Care Franchise, reporting to Andy Pawson, President and General Manager, Global Vision Care Franchise. As Global Head
- Allegro Ophthalmics to Present the Results of Its Phase 2 Risuteganib Intermediate Dry AMD Study at EURETINAhttps://modernod.com/news/allegro-ophthalmics-to-present-the-results-of-its-phase-2-risuteganib-intermediate-dry-amd-study-at-euretina/2476845/Allegro Ophthalmics announced that the results of its US phase 2 study evaluating risuteganib (Luminate) for the treatment of intermediate nonexudative age-related macular degeneration (dry AMD) will be presented during the European Society of Retina Specialists (EURETINA) Congress that is being
- Kowa Submits IND Application to the FDA to Begin Phase 2 Study of Ripasudil Hydrochloride Hydratehttps://modernod.com/news/kowas-submits-ind-application-to-the-fda-to-begin-phase-2-study-of-ripasudil-hydrochloride-hydrate/2476842/Kowa, which has been developing Ripasudil Hydrochloride Hydrate, a Rho kinase inhibitor, for the indication of corneal endothelial diseases, submitted an investigational new drug (IND) application to the FDA on August 30, 2019 in order to commence a phase 2 clinical
- ProtoKinetix: Tests Show AAGP-Preserved and Enabled Retinal Cells to Mature Without Compromise after 5-Month Milestonehttps://modernod.com/news/protokinetix-tests-show-aagp-preserved-and-enabled-retinal-cells-to-mature-without-compromise-after-5-month-milestone/2476822/ProtoKinetix updated shareholders regarding ongoing third stage testing of retinal cell replacement therapy at the University of British Columbia. As previously reported, the company demonstrated the ability of AAGP to protect transplanted cells in a preclinical experimental model of retinal dege
- Quantel Medical Announces Acquisition of Optotek Medicalhttps://modernod.com/news/quantel-medical-announces-acquisition-of-optotek-medical/2476821/Quantel Medical announced that it is acquiring ophthalmic medical device maker Optotek Medical. This acquisition comes after a long collaboration between the two companies through the development and supply of devices
- Iconic Therapeutics Signs Ophthalmology Option Agreement With Novartishttps://modernod.com/news/iconic-therapeutics-signs-ophthalmology-option-agreement-with-novartis/2476818/Iconic Therapeutics announced that the company has signed an agreement with Novartis in which Novartis will have an option on Iconic’s ophthalmology program, now in preclinical development. Novartis made an upfront payment and an equity investment in Iconic. The details of investment were not dis
- Trump Administration to Appeal Ruling Barring Proposed Drug Price Disclosure Policyhttps://modernod.com/news/trump-administration-to-appeal-ruling-barring-proposed-drug-price-disclosure-policy/2476816/The administration of US President Donald Trump plans to appeal a recent federal court decision striking down a Department of
- Nidek Launches the Mirante Scanning Laser Ophthalmoscopehttps://modernod.com/news/nidek-launches-the-mirante-scanning-laser-ophthalmoscope/2479546/Nidek has announced the launch of the Mirante Scanning Laser Ophthalmoscope. The Mirante is a multimodal fundus imaging platform that combines high definition SLO and OCT with ultra widefield imaging. The multimodal p